Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 versus IgPro10 crossover study in adults with diffuse cutaneous systemic sclerosis
2018-003149-41Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Mar 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of polyvalent human immunoglobulin in systemic sclerosis (SSc) (2 arms), sponsored by CSL Limited. Primary endpoint: Number and percentage of subjects with adverse events for IgPro20. Started Mar 2019; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2018-003149-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003149-41.